SEARCH RESULTS

329930 RESULTS

PF-05212377

THERAPEUTICS Pfizer PF-5212377 WYE-103760 SAM-760 Small Molecule Other Neurotransmitters Between 2009 and 2014, Wyeth and then Pfizer conducted four Phase 1 trials of PF-05212377 in about 230 healthy volunteers. One trial, conducted in France, evaluated the effect of

Carvedilol

THERAPEUTICS 1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol Procter & Gamble Coreg Artist Aucardic Dilatrend Kredex Small Molecule Unknown Carvedilol is being evaluated in an investigator-initiated study at the Alzheimer's Disease Resear

LY2886721

THERAPEUTICS Eli Lilly & Co. BACE inhibitor Small Molecule Amyloid-Related Lilly completed six Phase 1 studies of LY2886721’s safety, tolerability, and pharmacology in a total of 150 healthy volunteers and people with Alzheimer’s disease at doses of 1–70 mg. Singl

NeuroAD

THERAPEUTICS Neuronix Ltd Repetitive Transcranial Magnetic Stimulation rTMS-Cog Procedural Intervention Other Early studies on the NeuroAD device claimed improvements in ADAS-Cog scores after six weeks of daily 10 Hz TMS stimulation of the right and left dorsolateral

Atomoxetine

THERAPEUTICS Eli Lilly & Co. ATX Strattera Small Molecule Other Neurotransmitters Between 2003 and 2006, Eli Lilly conducted a six-month Phase 2/3 repurposing trial at eight sites in the United States to evaluate the effectiveness of 25-80 mg/day of atomoxetine in

HMTM

THERAPEUTICS Hydromethylthionine mesylate Leuco-methylthioninium bis(hydromethanesulfonate) TauRx Therapeutics Ltd LMTM LMTX, LMT-X TRx0237 Tau aggregation inhibitor (TAI) Methylene Blue Small Molecule Tau No information on Phase 1 trials of TRx0237 is available. A fo

Exenatide

THERAPEUTICS Exendin-4 Byetta Bydureon Small Molecule Other In 2010, an investigator-sponsored trial at University College London enrolled 44 people with moderate Parkinson's disease into an open-label study. Half the cohort injected themselves with 10 micrograms

Deep Brain Stimulation-fornix

THERAPEUTICS Functional Neuromodulation Ltd DBS-f Procedural Intervention Unknown In March 2007-June 2010, an open-label pilot study of bilateral DBS-f ran at the Toronto Western Hospital. Six volunteers with clinically diagnosed probable AD had electrodes implanted a

Ladostigil

THERAPEUTICS Avraham Pharmaceuticals Ltd Ladostigil hemitartrate TV3326 Small Molecule Cholinergic System In 2011 and 2012, Avraham Pharmaceuticals evaluated a six-month course of escalating doses of up to 80 mg twice daily of ladostigil in a Phase 2 study of 201 peop

Masitinib

THERAPEUTICS AB Science Masivet Kinavet AB1010 Masitinib mesylate Small Molecule Other From 2006 to 2009, AB Science conducted a Phase 2 trial comparing 3 and 6 mg/kg/day of masitinib or placebo, taken twice daily for six months as an add-on therapy to cholinesterase

Gantenerumab

THERAPEUTICS Chugai Pharmaceutical Co., Ltd. Hoffmann-La Roche RO4909832 RG1450 R1450 Immunotherapy (passive) Amyloid-Related Four Phase 1 trials conducted internationally in a total of 308 patients have tested the safety, tolerability, pharmacokinetics, and pharmacod

Leqembi

THERAPEUTICS BioArctic AB Biogen Eisai Co., Ltd. Lecanemab-irmb BAN2401 mAb158 Immunotherapy (passive) Amyloid-Related A multicenter Phase 1 trial tested the safety, tolerability, and pharmacokinetics of single and multiple ascending intravenous doses of BAN2401 in 80

Verubecestat

THERAPEUTICS Merck MK-8931, MK-8931-009 BACE inhibitor Small Molecule Amyloid-Related Phase 1 included four public studies of a total of 68 healthy controls, patients with mild to moderate Alzheimer's disease, and people with renal insufficiency, held in Japan an

Riluzole

THERAPEUTICS 6-trifluoromethoxy-2-benzothiazolamine Sanofi Rilutek® RP 54274 Small Molecule Other Neurotransmitters Other Riluzole was approved for ALS because in several clinical trials it modestly extended survival or time to insertion of a breathing tube. Initial c

Current Filters

No filters selected

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE